Mental illness represents the leading cause of disability burden in Australia. Given an ageing population and the ongoing demands of the modern lifestyle, the incidence of neurodegenerative and neuropsychiatric disease is on the rise.
Unfortunately, the attrition rate associated with novel drug discovery for central nervous system (CNS) disorders is unacceptably high. This reflects the difficulty in understanding and treating neurodegenerative and neuropsychiatric diseases, including schizophrenia, anxiety and depression, which are complex and polygenic in nature.
Studies at DDB focus on understanding how modulation of G protein-coupled receptor targets in the CNS can provide new insights into mechanisms underlying neurological disease — in particular deficits associated with schizophrenia — and identify novel therapeutic modalities.
|Analytical Neuropharmacology||Cancer & Neural-Immune Regulation|
|Cellular & Molecular Metabolism||Endocrine & Neuropharmacology|
|Metabolic GPCR Biology||Molecular & Translational Drug Discovery|
|Spatial Organisation of Signalling||Stem Cell Biology|